Insight Molecular Diagnostics (IMDX) Shares Outstanding (Weighted Average) (2015 - 2026)

Insight Molecular Diagnostics has disclosed Shares Outstanding (Weighted Average) across 12 years of filings, most recently posting $760866.0 for Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $760866.0, down 97.04% year-over-year; the trailing twelve-month figure through Mar 2026 was $760866.0 (down 97.04% YoY), and the FY2025 annual result was $30.5 million, up 133.16% from the prior year.
• Shares Outstanding (Weighted Average) came in at $760866.0 for Q1 2026 at Insight Molecular Diagnostics, roughly flat from $760866.0 in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $92.2 million in Q1 2022 to a low of $5135.0 in Q2 2022.
• The 5-year median for Shares Outstanding (Weighted Average) is $8.3 million (2023), against an average of $15.4 million.
• Across the five-year window, Shares Outstanding (Weighted Average) sank 99.99% in 2022 and surged 152562.72% in 2023, its largest moves.
• Insight Molecular Diagnostics' Shares Outstanding (Weighted Average) stood at $5.5 million in 2022, then surged by 38.1% to $7.7 million in 2023, then soared by 70.84% to $13.1 million in 2024, then tumbled by 94.18% to $760866.0 in 2025, then changed by 0.0% to $760866.0 in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $760866.0 (Q1 2026), $760866.0 (Q4 2025), and $29.9 million (Q3 2025), per Business Quant data.